Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C11H12NO3.Na |
| Molecular Weight | 229.2076 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 0 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Na+].CC(=O)NC(CC1=CC=CC=C1)C([O-])=O
InChI
InChIKey=RBMBEFVVHHNLAR-UHFFFAOYSA-M
InChI=1S/C11H13NO3.Na/c1-8(13)12-10(11(14)15)7-9-5-3-2-4-6-9;/h2-6,10H,7H2,1H3,(H,12,13)(H,14,15);/q;+1/p-1
DescriptionCurator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/7340854
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/7340854
AFALANINE was developed by Medea Research in Italy and licensed to Pulitzer. Phase III clinical trials of MR 708 were completed by Pulitzer. Antidepressant; Antiparkinsonian; Neuroprotectant; Nootropic, Dopamine receptor agonist, was used to treat Major depressive disorder.
CNS Activity
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
6Z92N83B5U
Created by
admin on Sat Dec 16 08:23:52 GMT 2023 , Edited by admin on Sat Dec 16 08:23:52 GMT 2023
|
PRIMARY | |||
|
23686419
Created by
admin on Sat Dec 16 08:23:52 GMT 2023 , Edited by admin on Sat Dec 16 08:23:52 GMT 2023
|
PRIMARY | |||
|
74407-30-0
Created by
admin on Sat Dec 16 08:23:52 GMT 2023 , Edited by admin on Sat Dec 16 08:23:52 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD
